<DOC>
	<DOC>NCT01410916</DOC>
	<brief_summary>This protocol is designed to collect safety and efficacy data on patients that have been or will be treated with eculizumab for STEC-HUS, in the context of the 2011 STEC-HUS epidemic in Germany.</brief_summary>
	<brief_title>Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)</brief_title>
	<detailed_description />
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Shiga Toxins</mesh_term>
	<criteria>1. Patient must be willing and able to give written informed consent/Assent. 2. Adults, adolescents, or pediatric (≥2 months and ≥5kg) patients 3. Patient has been diagnosed with Escherichia Coli HemolyticUremic Syndrome (STECHUS) 1. Known complement regulatory mutation or family history of complement regulatory mutation 2. Unresolved systemic meningococcal disease 3. 3. Hypersensitivity to eculizumab, to murine proteins or to one of the excipients</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>STEC-HUS</keyword>
	<keyword>Shiga-like toxin-producing Escherichia Coli Hemolytic-Uremic Syndrome</keyword>
	<keyword>uncontrolled complement activation</keyword>
</DOC>